Navigation Links
Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
Date:9/13/2010

rter of fiscal 2010.  The increase in R&D expenses in 2011 was mainly due to costs associated with the development and testing of the Company's four drug compounds and the acquisition of Tumorgrafts as the Company continues to expand its tumorgraft platform.

General and administrative expenses for first quarter of fiscal 2011 were $738,000 as compared to $806,000 in fiscal 2010.  The decrease was primarily attributable to the Company's consolidation of its operations to Baltimore, Maryland.

For the first quarter of fiscal 2011, the Company reported a net loss of $591,000, or ($0.02) per share, compared to a net loss of $1.0 million, or ($0.03) per share, in the corresponding quarter of fiscal 2010.  In addition to the factors described above, the Company's net losses reflect non-cash expenses, i.e., share-based compensation and depreciation, of $180,000 or ($0.01) per share, in the first quarter of 2011 compared to $58,000, or ($0.00) per share, in the first quarter of 2010.

The Company's cash position on July 31, 2010 was $2.1 million compared to $2.6 million on April 30, 2010.

First Quarter Highlights:

  • Experienced an increase in top-line revenues of 66% with overall gross margins increasing from 31% to 66%, year-over-year;
  • Experienced year-over-year top-line revenue growth of 679% in the Preclinical eValuation business;
  • Continued to expand its Biomerk Tumorgraft platform to approximately 350 tumorgrafts which are available and/or in development at July 31, 2010, representing all of the major solid tumor indications;
  • Hired a Preclinical Sales Director to oversee direct sales of Preclinical eValuation services; and
  • Began to offer genome sequencing as part of its Personalized Oncology services.

  • David Sidransky, M.D., Chairman of the Board of Champions Biotechnology, Inc., noted, "The 2011 first quarter results are positive.  As we move into 2011, we continue to see
    '/>"/>

    SOURCE Champions Biotechnology, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
    2. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
    3. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
    4. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
    5. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
    6. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
    7. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
    8. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
    9. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
    10. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
    11. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... Aug. 21, 2014 Mathematic studies at the ... , and funded by the Jeffrey Epstein VI Foundation ... can be visually identified for elimination. These aggressive cells are ... which shows a topological map of what to look for ... research, for while tumor cells can be extracted from biopsy, ...
    (Date:8/21/2014)... Calif. , Aug. 21, 2014  Four-dimensional ... and behaviors based on external stimuli such as ... to have a disruptive effect in multiple industries.  ... the business landscape by printing objects ranging from ... and automotive sectors. Logo - ...
    (Date:8/21/2014)... (PRWEB) August 21, 2014 ... biopharmaceutical contract development and manufacturing organization (CMO) announced ... Pharmaceuticals, Inc., an oncology company focused on the ... cancer, to manufacture the anti-prostate specific membrane antigen ... product candidate. Under the agreement the antibody ...
    (Date:8/20/2014)... 2014 Clintrax Global, Inc., a worldwide ... Raleigh, NC , recently announced the ... President of Administration. As Vice ... processes, including their alignment with company objectives and ... as an HR executive, specializing in needs assessments, ...
    Breaking Biology Technology:Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Clintrax Global, Inc. Announces Addition to Executive Team 2
    ... MISSISSAUGA, ON, Oct. 22 /PRNewswire-FirstCall/ - YM BioSciences ... an oncology company that identifies,develops and commercializes differentiated ... of Directors has adopted a renewed,Shareholder Rights Plan ... fair treatment of shareholders in connection with any ...
    ... Call and Webcast to Follow, THE WOODLANDS, Texas, ... will release its third quarter 2007,financial results on Tuesday, ... will hold a conference call to discuss the,company,s results ... at 5:00 p.m. Eastern Time on October 30, 2007. ...
    ... Orchid Cellmark Inc.,(Nasdaq: ORCH ), a ... announced that it has signed a definitive purchase,agreement ... Inc.,for a purchase price of $5.6 million in ... Cellmark restricted common stock. The purchase price is,subject ...
    Cached Biology Technology:YM Biosciences announces adoption of renewed Shareholders' Rights Plan 2YM Biosciences announces adoption of renewed Shareholders' Rights Plan 3Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007 2Orchid Cellmark to Purchase ReliaGene Technologies, Inc. 2Orchid Cellmark to Purchase ReliaGene Technologies, Inc. 3
    (Date:8/21/2014)... study aimed at improving the food intake, health and ... homes is among three projects at the University of ... the Canadian Institutes of Health Research (CIHR). , ... Sciences at Waterloo, and a Schlegel research chair in ... to investigate why many Canadians living in long-term care ...
    (Date:8/21/2014)... to Wednesday, Oct. 18-22, 2014 , WHERE: ... Drive, San Diego, CA 92101 , WHAT: ... presentations of the latest research in human genetics. ... featuring high-scoring abstracts on rare genetic variants in ... and treatment for sun sensitivity (Saturday, Oct. 18, ...
    (Date:8/21/2014)... Researchers from North Carolina State University have developed a ... The model has applications for creating new materials as ... , "Our new technique allows us to model much ... so much more quickly," says Nan Li, lead author ... student in NC State,s Department of Materials Science and ...
    Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
    ... moss on a tree trunk always points north. According to ... may also provide a new "compass" for stem cell research, ... purposes. Dr. Nir Ohad of Tel Aviv ... the University of Freiburg have discovered a new use for ...
    ... a lot from an animal. By manipulating the DNA of ... deal about the genes and molecules behind many of life,s ... in people as they do in "model" animals. But if ... humans, ability to learn language from one another, you need ...
    ... of the research was to gather information on the effects ... and dynamic characteristics of plankton in the estuaries. The ... work entitled Impact of climate variability on the pelagic ecosystem ... Biscay): a time series analysis. He has studied the estuaries ...
    Cached Biology News:Telltale moss 2Transgenic songbirds provide new tool to understand the brain 2University of Basque Country research study on effects of climate on plankton in the estuaries 2
    ... The European Collection of Cell Cultures (ECACC) ... West of the West of England, Bristol, ... the quality control of HER2, oestrogen and ... paraffin wax sections of formalin fixed, breast ...
    ... 3C protease from human rhinovirus (HRV 3C) ... brand line of restriction grade proteases. The ... 6XHis-fusion protein, which recognizes the same cleavage ... small, 22 KDa size of the protease, ...
    ...
    ... Continuing a tradition of progressive centrifuge design ... series. The Centra-CL3 and Centra-CL3R (refrigerated) general ... laboratory., Quality Control Over Sample Preparation ... lock up to 99 protocols and has ...
    Biology Products: